Strong start to 2024!

The Group’s sales amounted to 58.6 (42.3) MSEK for the first quarter of the year, and as result of increased sales in combination with stabilized costs and return on investments the Group’s EBITDA amounted to 11,7 (2,7) MSEK. The net result totaled 13.1 (-2.5) MSEK for the period.
Cash flow from operating activities amounted to 10.1 (-1.7) MSEK for the quarter.

A total number of 154 (140) scalp cooling systems were installed around the world in the first three months of the year, with the order book containing an additional 153 (162) systems.

Average Daily Treatment Revenue (ADTR) amounted to 38.8 TUSD (403.0 TSEK) for Q1 2024, corresponding to an increase of 22.6% compared to 32.0 TUSD (333.9 TSEK) for Q1 2023. Recurring income increased from 23.7 MSEK in Q1 2023 to 29.9 MSEK for the same period in 2024.

Significant events during the reporting period
In February the Paxman Group has increased its investment from 20% to 49% in Paxman GmbH, working our partner Novidion to relaunch Paxman in the German Direct market. The German market is an excellent opportunity for the company and with the UK company’s increased involvement traction is expected to improve through 2024.
In March, Paxman was honoured to receive the Export Achievement Award during the prestigious Medilink North of England Healthcare Business awards, recognising our outstanding growth and success in international markets. Paxman’s R&D team were also runners-up for the Partnership with Academia category for our collaborative efforts with academic institutions.
 
Significant events after the reporting period
During May, Susy Brown will be leaving Paxman as Head of Brand & Marketing after close to 6 years in the business. She will be pursing a new opportunity and will be replaced in the role by Louise Apsey-Smith. You can find out more about Louise at www.paxman.se/investor-centre/corporate-governance
In May, the partnership between the University of Huddersfield and Paxman was awarded an outstanding grade from UK Research and Innovation. The award is the culmination of a two-year Knowledge Transfer Partnership (KTP) that designed and developed the Paxman device for the unmet clinical need of chemotherapy-induced peripheral neuropathy (CIPN).

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 5,000 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN’s scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK), Houston, Texas (US) and Toronto, Ontario (CA).

The PAXMAN share is listed on Nasdaq First North Growth Market.
FNCA Sweden AB is the company’s Certified Adviser.

This information is information that PAXMAN is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-05-23 09:00 CEST.

Attachments

Paxman AB Interim Report Q1 2024 English

© Modular Finance, source Nordic Press Releases